Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study.

Brett MarinelliEdward KimAntonio D'AlessioMario CedilloIshan SinhaNeha DebnathMasatoshi KudoNaoshi NishidaAnwaar SaeedHannah HildebrandAhmed O KasebYehia I AbugabalAnjana PillaiYi-Hsiang HuangUqba KhanMahvish MuzaffarAbdul Rafeh NaqashRahul PatelAaron FischmanVivian BishayDominik BettingerMax SungCelina AngMyron SchwartzDavid James PinatoThomas Marron

Published in: Journal for immunotherapy of cancer (2022)

TACE can be safely integrated with programmed cell death 1 blockade and may lead to a significant delay in tumor progression and disease downstaging in selected patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
radiofrequency ablation
patient reported outcomes
long non coding rna